N. Kumarasamy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
N. Kumarasamy has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Suniti Solomon
Y. R. Gaitonde Center for AIDS Research and Education, University of Madras, Chennai, India
3 shared publicationsKenneth H. Mayer
Miriam Hospital, Brown University, Providence, Rhode Island
2 shared publicationsR. Hemalatha
Y. R. Gaitonde Center for AIDS Research and Education, University of Madras, Chennai, India
2 shared publicationsS. P. Thyagarajan
Department of Microbiology, Dr.ALM Post Graduate Institute of Basic Medical Sciences, University of Madras, Chennai, India
2 shared publicationsTimothy P. Flanigan
Miriam Hospital, Brown University, Providence, Rhode Island
2 shared publicationsAnish P Mahajan
1 shared publication
Latest Publications
- Open Access
- 1 January 2003
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 36 (1) , 79-85
Natural History of Human Immunodeficiency Virus Disease in Southern India
There are few reports of the natural history of human immunodeficiency virus (HIV) infection from Asia. In a retrospective analysis of 594 patients (
- 1 January 2003
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 36 (1) , 79-85
Open AccessNatural History of Human Immunodeficiency Virus Disease in Southern India
There are few reports of the natural history of human immunodeficiency virus (HIV) infection from Asia. In a retrospective analysis of 594 patients (
- 1 December 2002
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 31 (4) , 378-383
Total Lymphocyte Count (TLC) Is a Useful Tool for the Timing of Opportunistic Infection Prophylaxis in India and Other Resource-Constrained Countries
In most resource-constrained countries, CD4 cell count testing is prohibitively expensive for routine clinical use and is not widely available. As a result, physicians are often required to make decisions about opportunistic infection (OI) chemoprophylaxis without a laboratory evaluation of HIV stage and level of immunosuppression. To evaluate the correlation of total lymphocyte count (TLC), an inexpensive and widely available parameter, to CD4 count. To determine a range of TLC cutoffs for the initiation of OI prophylaxis that is appropriate for resource-constrained settings. Spearman correlation between CD4 count and TLC was assessed in patients attending an HIV/AIDS clinic in South India. Positive predictive value (PPV), negative predictive value (NPV), and sensitivity and specificity of various TLC cutoffs were computed for CD4 count <200 cells/mm3 and <350 cells/mm3. Correlation and statistical indices computed for all patients and for patients dually infected with HIV and active tuberculosis. High degree of correlation was noted between 650 paired CD4 and TLC counts (r = 0.744). TLC <1400 cells/mm3 had a 76% PPV, 86% NPV, and was 73% sensitive, 88% specific for CD4 count <200 cells/mm3. TLC <1700 cells/mm3 had a 86% PPV, 69% NPV, and was 70% sensitive, 86% specific for CD4 count <350 cells/mm3. The cost of a single CD4 count in India is approximately US $30, whereas the cost of a single TLC is US $0.80. TLC could serve as a low-cost tool for determining both a patient’s risk of OI and when to initiate prophylaxis in resource-constrained settings. PPV, NPV, sensitivity, and specificity maximally aggregated at TLC <1400 cells/mm3 for CD4 <200 cell/mm3 and TLC <1700 cells/mm3 for CD4 <350 cells/mm3. Selection of appropriate TLC cutoffs for prophylaxis administration should be made on a regional basis depending on OI incidence, antimicrobial resistance patterns, and availability of the antimicrobials.
- 1 December 2002
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 31 (4) , 378-383
Total Lymphocyte Count (TLC) Is a Useful Tool for the Timing of Opportunistic Infection Prophylaxis in India and Other Resource-Constrained Countries
In most resource-constrained countries, CD4 cell count testing is prohibitively expensive for routine clinical use and is not widely available. As a result, physicians are often required to make decisions about opportunistic infection (OI) chemoprophylaxis without a laboratory evaluation of HIV stage and level of immunosuppression. To evaluate the correlation of total lymphocyte count (TLC), an inexpensive and widely available parameter, to CD4 count. To determine a range of TLC cutoffs for the initiation of OI prophylaxis that is appropriate for resource-constrained settings. Spearman correlation between CD4 count and TLC was assessed in patients attending an HIV/AIDS clinic in South India. Positive predictive value (PPV), negative predictive value (NPV), and sensitivity and specificity of various TLC cutoffs were computed for CD4 count <200 cells/mm3 and <350 cells/mm3. Correlation and statistical indices computed for all patients and for patients dually infected with HIV and active tuberculosis. High degree of correlation was noted between 650 paired CD4 and TLC counts (r = 0.744). TLC <1400 cells/mm3 had a 76% PPV, 86% NPV, and was 73% sensitive, 88% specific for CD4 count <200 cells/mm3. TLC <1700 cells/mm3 had a 86% PPV, 69% NPV, and was 70% sensitive, 86% specific for CD4 count <350 cells/mm3. The cost of a single CD4 count in India is approximately US $30, whereas the cost of a single TLC is US $0.80. TLC could serve as a low-cost tool for determining both a patient’s risk of OI and when to initiate prophylaxis in resource-constrained settings. PPV, NPV, sensitivity, and specificity maximally aggregated at TLC <1400 cells/mm3 for CD4 <200 cell/mm3 and TLC <1700 cells/mm3 for CD4 <350 cells/mm3. Selection of appropriate TLC cutoffs for prophylaxis administration should be made on a regional basis depending on OI incidence, antimicrobial resistance patterns, and availability of the antimicrobials.
- 1 November 2002
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 2 (11) , 656-657
Monitoring HIV treatment in the developing world
- 1 November 2002
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 2 (11) , 656-657
Monitoring HIV treatment in the developing world